

wherein:

X is an amino acid selected from the group consisting of I, L, Nle (norleucine);

B is an amino acid selected from the group consisting of K, W, F, Y, Ornithine;

Z is S and can be optionally linked via ester or thio-ester bonds with acyl group containing 12-22 carbon atoms;

a is an integer from 1 to 19;

b is an integer from 1 to 19;

c is an integer from 1 to 21;

d is an integer from 0 to 20;

e is 0 or 1;

f is 0 or 1;

n is 0 or 1;

m is 0 or 1,

with the following conditions:

$n + m > 0$;

$f \geq e$;

$(X_a B)(X_b B)_n (X_c B)_m X_d$ is a sequence having a maximum of 22 amino acids.

7. (Amended) A SP-C analog according to Claim 1, in which Ser residues are acylated.

8. (Amended) A SP-C analog according to Claim 1, in which B is Lysine or Phenylalanine and X is Leucine, Isoleucine or Norleucine.

10. (Amended) A synthetic surfactant comprising at least one SP-C analogue as claimed in Claim 1 in admixture with lipids and phospholipids.

12. (Amended) A synthetic surfactant according to Claim 10, further comprising SP-B or an active derivative thereof or a polymyxin.

13. (Amended) A synthetic surfactant according to Claim 10, in form of solution, dispersion, suspension, dry powder.

Please add new Claims 17-27 as follows:

17. (New) The SP-C analogue as claimed in claim 1 wherein the $(X_aB)(X_bB)_n(X_cB)_mX_d$ sequence has from 10 to 22 amino acids.

18. (New) The SP-C analogue as claimed in claim 7 wherein the Ser residues are acylated with palmitoyl groups.

19. (New) A pharmaceutically active synthetic surfactant comprising the SP-C analogues of Claim 1.

20. (New) A method of treating a surfactant deficiency comprising administering the SP-C analogues of Claim 1.

21. (New) A pharmaceutically active synthetic surfactant comprising the surfactant of Claim 10, wherein said surfactant comprises polymyxin.

22. (New) A pharmaceutically active synthetic surfactant comprising the surfactant of Claim 10, wherein said surfactant comprises polymyxin B.

23. (New) A method of treating surfactant deficiencies or dysfunction, or serious otitis media comprising administering the surfactant of Claim 10 wherein said surfactant comprises polymyxin.

24. (New) A method of treating surfactant deficiencies or dysfunction, or serious otitis media comprising administering the surfactant of Claim 10 wherein said surfactant comprises polymyxin B.